The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain
By John M. Lamar, Patrick Stern, Hui Liu, Jeffrey W. Schindler, Zhi-Gang Jiang, R. Hynes. Proceedings of the National Academy of Sciences of the United States of America, 2012
626 citations recorded by the source corpus.
Subfields: Cell Biology
View Paper: https://www.semanticscholar.org/paper/312a158f2a88cd0721fea085821ef094546b0a0d
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cell Biology
Citations in the corpus
- The Hippo Signaling Pathway in Development and Disease (2019, background): “KRAS and YAP1 converge to regulate EMT and tumor survival.”
- KRAS and YAP1 converge to regulate EMT and tumor survival (2014, background): “In addition, YAP1 is also implicated in the epithelial-to-mesenchymal transition (EMT) and the metastatic potential of mammary epithelial cells (Lamar et al., 2012; Overholtzer et al., 2006).”
- Dynamic EMT: a multi‐tool for tumor progression (2021, positive): “YAP/TAZ overexpression and activation is crucial to mediate EMT and cell plasticity in skin cancer and is sufficient to induce EMT in MCF 10 A non-cancerous mammary epithelial cells.”
- The biology of YAP/TAZ: hippo signaling and beyond. (2014, background): “Third, YAP/TAZ have been recently reported to be instrumental for breast and lung cancer metastasis in animal models, and associated with metastatic diseases in human patients (13, 38, 85, 108, 109).”
- YAP/TAZ at the roots of cancer (2016, background): “In contrast, YAP overexpression can confer lung metastatic abilities to otherwise benign mouse mammary tumor cell lines (Lamar et al., 2012).”
- The Hippo pathway: regulators and regulations. (2013, background): “The role of YAP in promoting cancer metastasis has also recently been demonstrated in mice (Chen et al. 2012; Lamar et al. 2012).”
- The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment (2013, positive): “…making cells more sensitive to chemotherapeutic reagents 122 , inhibition of cancer stem cell formation 132 , and reduction of metastatic potential 194, 197 , suggesting that targeting YAP may be effective in modulating a number of cancer cell properties that are required for their expansion,…”
- The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease (2014, background): “…mutations that disrupt the binding of TAZ or YAP to TEADs abolish their ability to promote proliferation and tumorigenic overgrowth phenotypes (Lamar et al., 2012; Zhang et al., 2009; Zhao et al., 2008), suggesting that control of TEAD activity is crucial for many of the TAZ/YAP functions…”